NLTX Annual Operating Profit
-$59.10 M
+$1.60 M+2.64%
31 December 2022
Summary:
As of February 5, 2025, NLTX annual operaing income is -$59.10 million, with the most recent change of +$1.60 million (+2.64%) on December 31, 2022. During the last 3 years, it has fallen by -$35.85 million (-154.26%).NLTX Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX Quarterly Operating Profit
-$5.57 M
-$2.50 M-81.64%
30 September 2023
Summary:
As of February 5, 2025, NLTX quarterly operating income is -$5.57 million, with the most recent change of -$2.50 million (-81.64%) on September 30, 2023. Over the past year, it has increased by +$8.04 million (+59.08%).NLTX Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX TTM Operating Profit
-$34.60 M
+$8.04 M+18.85%
30 September 2023
Summary:
As of February 5, 2025, NLTX TTM operating income is -$34.60 million, with the most recent change of +$8.04 million (+18.85%) on September 30, 2023. Over the past year, it has increased by +$25.42 million (+42.35%).NLTX TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NLTX Operating Profit Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.6% | +59.1% | +42.4% |
| 3 y3 years | -154.3% | +44.7% | +7.2% |
| 5 y5 years | -15.6% | +63.4% | -48.9% |
NLTX Operating Profit High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | +669.4% | -307.0% | +3371.4% |
Neoleukin Therapeutics Operating Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$5.57 M(+81.6%) | -$34.60 M(-18.9%) |
| June 2023 | - | -$3.07 M(-73.8%) | -$42.64 M(-23.1%) |
| Mar 2023 | - | -$11.72 M(-17.8%) | -$55.45 M(-6.2%) |
| Dec 2022 | -$59.10 M(-2.6%) | -$14.25 M(+4.7%) | -$59.10 M(-1.5%) |
| Sept 2022 | - | -$13.61 M(-14.3%) | -$60.02 M(-3.0%) |
| June 2022 | - | -$15.87 M(+3.3%) | -$61.86 M(+1.2%) |
| Mar 2022 | - | -$15.37 M(+1.3%) | -$61.12 M(+0.7%) |
| Dec 2021 | -$60.70 M(+46.1%) | -$15.17 M(-1.8%) | -$60.70 M(+4.4%) |
| Sept 2021 | - | -$15.45 M(+2.2%) | -$58.16 M(+10.2%) |
| June 2021 | - | -$15.12 M(+1.2%) | -$52.79 M(+11.3%) |
| Mar 2021 | - | -$14.95 M(+18.3%) | -$47.43 M(+14.1%) |
| Dec 2020 | -$41.55 M(+78.8%) | -$12.64 M(+25.4%) | -$41.55 M(+11.5%) |
| Sept 2020 | - | -$10.08 M(+3.1%) | -$37.27 M(-4.4%) |
| June 2020 | - | -$9.77 M(+7.7%) | -$39.00 M(+31.5%) |
| Mar 2020 | - | -$9.07 M(+8.6%) | -$29.66 M(+27.6%) |
| Dec 2019 | -$23.24 M(-28.8%) | -$8.36 M(-29.2%) | -$23.24 M(+15.1%) |
| Sept 2019 | - | -$11.80 M(+2657.0%) | -$20.19 M(-14.4%) |
| June 2019 | - | -$428.00 K(-83.9%) | -$23.58 M(+15.2%) |
| Mar 2019 | - | -$2.66 M(-49.8%) | -$20.47 M(-37.3%) |
| Dec 2018 | -$32.62 M | -$5.30 M(-65.1%) | -$32.62 M(-25.6%) |
| Sept 2018 | - | -$15.20 M(-664.9%) | -$43.86 M(+7.7%) |
| June 2018 | - | $2.69 M(-118.2%) | -$40.73 M(-29.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$14.82 M(-10.4%) | -$57.41 M(+12.3%) |
| Dec 2017 | -$51.12 M(+35.8%) | -$16.53 M(+37.0%) | -$51.12 M(+11.0%) |
| Sept 2017 | - | -$12.07 M(-13.8%) | -$46.05 M(+9.0%) |
| June 2017 | - | -$13.99 M(+64.2%) | -$42.26 M(+7.4%) |
| Mar 2017 | - | -$8.52 M(-25.7%) | -$39.33 M(+4.5%) |
| Dec 2016 | -$37.65 M(+76.4%) | -$11.46 M(+38.4%) | -$37.65 M(+18.5%) |
| Sept 2016 | - | -$8.28 M(-25.1%) | -$31.77 M(+11.8%) |
| June 2016 | - | -$11.06 M(+61.9%) | -$28.41 M(+28.3%) |
| Mar 2016 | - | -$6.83 M(+22.2%) | -$22.14 M(+3.7%) |
| Dec 2015 | -$21.34 M(-4.6%) | -$5.59 M(+13.7%) | -$21.34 M(-9.4%) |
| Sept 2015 | - | -$4.92 M(+2.6%) | -$23.57 M(-5.6%) |
| June 2015 | - | -$4.79 M(-20.6%) | -$24.96 M(-3.3%) |
| Mar 2015 | - | -$6.04 M(-22.8%) | -$25.80 M(+15.3%) |
| Dec 2014 | -$22.38 M(+138.6%) | -$7.82 M(+23.9%) | -$22.38 M(+24.3%) |
| Sept 2014 | - | -$6.31 M(+12.0%) | -$18.00 M(+19.1%) |
| June 2014 | - | -$5.63 M(+115.4%) | -$15.11 M(+36.2%) |
| Mar 2014 | - | -$2.62 M(-24.1%) | -$11.09 M(+17.1%) |
| Dec 2013 | -$9.38 M(+22.1%) | -$3.44 M(+0.8%) | -$9.47 M(+57.1%) |
| Sept 2013 | - | -$3.42 M(+111.3%) | -$6.03 M(+130.7%) |
| June 2013 | - | -$1.62 M(+62.2%) | -$2.61 M(+162.2%) |
| Mar 2013 | - | -$996.80 K | -$996.80 K |
| Dec 2012 | -$7.68 M | - | - |
FAQ
- What is Neoleukin Therapeutics annual operaing income?
- What is the all time high annual operating profit for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics annual operating profit year-on-year change?
- What is Neoleukin Therapeutics quarterly operating income?
- What is the all time high quarterly operating profit for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics quarterly operating profit year-on-year change?
- What is Neoleukin Therapeutics TTM operating income?
- What is the all time high TTM operating profit for Neoleukin Therapeutics?
- What is Neoleukin Therapeutics TTM operating profit year-on-year change?
What is Neoleukin Therapeutics annual operaing income?
The current annual operating profit of NLTX is -$59.10 M
What is the all time high annual operating profit for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high annual operaing income is -$7.68 M
What is Neoleukin Therapeutics annual operating profit year-on-year change?
Over the past year, NLTX annual operaing income has changed by +$1.60 M (+2.64%)
What is Neoleukin Therapeutics quarterly operating income?
The current quarterly operating profit of NLTX is -$5.57 M
What is the all time high quarterly operating profit for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high quarterly operating income is $2.69 M
What is Neoleukin Therapeutics quarterly operating profit year-on-year change?
Over the past year, NLTX quarterly operating income has changed by +$8.04 M (+59.08%)
What is Neoleukin Therapeutics TTM operating income?
The current TTM operating profit of NLTX is -$34.60 M
What is the all time high TTM operating profit for Neoleukin Therapeutics?
Neoleukin Therapeutics all-time high TTM operating income is -$996.80 K
What is Neoleukin Therapeutics TTM operating profit year-on-year change?
Over the past year, NLTX TTM operating income has changed by +$25.42 M (+42.35%)